Susanna Pajula

Susanna Pajula

Auto-generated profile, based on publicly available information

Susanna Pajula

Department of Plastic and General Surgery, Turku University Hospital, Turku, Finland

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
SPSusanna Pajula
Susanna Pajula
JJJanne Jyränki
Janne Jyränki
ETErkki Tukiainen
Erkki Tukiainen
VKVirve Koljonen
Virve Koljonen

26 January 2023 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Open access
PDF file
KSKaukonen Sesilia
Kaukonen Sesilia
PSPajula Susanna
Pajula Susanna
VKVirve Koljonen
Virve Koljonen
GMGissler Mika
Gissler Mika
UVUlander Veli-Matti
Ulander Veli-Matti
KMKaijomaa Marja
Kaijomaa Marja
Purpose: Overweight and obesity are major risk factors for perinatal morbidity and mortality, and the need for bariatric surgery (BS) among fertile-aged women is increasing. This study evaluates the outcome of post-BS pregnancies and deliveries. Methods: All 20–45-year-old patients delivering between 2004 and 2016 in Finland were included. Patients with previous BS were identified from the hospital discharge register, and the medical birth register was queried for data on pregnancies, deliveries, and perinatal outcomes. The data were matched using personal identification codes, and the outcomes of women with previous BS were compared with those of other pregnancies. Results: Women with previous BS (n = 314) constituted the bariatric group. When compared with the non-bariatric group (n = 750,019), they were older (p < 0.001), heavier (p < 0.001) and had more previous pregnancies (p < 0.001). The overall incidence of pregnancy-induced hypertension (p = 0.002), gestational diabetes (GDM) (p = 0.018), pre-term contractions (p = 0.023), pre-term delivery (p = 0.003), labour induction (p < 0.001), planned (p = 0.001) and unplanned (p = 0.036) caesarean sections and low birthweight infants (p < 0.001) were significantly higher in the bariatric group. When compared with body mass index–specific categories, the main outcomes were increased incidence of GDM and small for gestational age (SGA) newborns in the bariatric group. Conclusion: BS can be considered a safe and advisable treatment for obesity among fertile-aged women. The pregnancy outcome is associated with post-BS weight, but the risk for GDM and small for gestational-age newborns is increased.

10 August 2020 in Journal of Plastic Surgery and Hand Surgery
Verified
Journal Article
Open access
SPSusanna Pajula
Susanna Pajula
MGMika Gissler
Mika Gissler
JJJanne Jyränki
Janne Jyränki
ETErkki Tukiainen
Erkki Tukiainen
VKVirve Koljonen
Virve Koljonen
Massive weight loss might lead to excess skin folds causing functional, physical, and psychosocial discomfort. Following bariatric procedures, an increasing number of patients are seeking lower body contouring surgery (LBCS). The proportion of bariatric patients who undergo LBCS is largely unknown. The aim of this current study was to analyse the incidence and realization of LBCS in bariatric patients in Finland. National retrospective register linkage study including all adult patients who received bariatric surgery in Finland during 1998–2016. The data were obtained from the Finnish national health registers maintained by the Finnish Institute for Health and Welfare. Altogether 1089 (14.1%) of 7703 bariatric patients underwent LBCS during the study period. The majority of the LBCS procedures were abdominoplasty (89%). Median latency between bariatric surgery and LBCS was 31 months. The patients with LBCS were younger (p < 0.001) and received sleeve gastrectomy (p < 0.001). We revealed an annual correlation between LBCS and bariatric procedures (r = 0.683). With a two-year latency between the bariatric and post-bariatric operations, the correlation co-efficiency was strong (r = 0.927). LBCS operations ranged from 5 to 215 per hospital district. Most LBCSs (97.3%) were performed in public hospitals, and some (41%) were performed in university hospitals. This study shows that only 14.1% of bariatric patients undergo LBCS. There is a correlation between bariatric procedures and succeeding plastic surgical reconstructive procedures.

16 October 2025 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Open access
SPSusanna Pajula
Susanna Pajula
ASAnne Saarikko
Anne Saarikko
SSSinikka Suominen
Sinikka Suominen
IKIlkka Kaartinen
Ilkka Kaartinen
JKJuha Kiiski
Juha Kiiski
PHPauliina Hartiala
Pauliina Hartiala
Lymfactin® is a gene-therapy vector encoding vascular endothelial growth factor C designed to promote lymphatic vessel growth. It is administered during vascularized lymph node transfer (VLNT) to treat breast cancer-related lymphedema. This study presents the final efficacy and long-term safety results of the Lymfactin® Phase I trial. Between 2016 and 2018, 12 patients with breast cancer-related lymphedema received a therapeutic dose of Lymfactin® injected into the VLNT flap with or without autologous breast reconstruction. Patients were followed up annually for 4 years. The mean seven-day swelling volume, defined as the volume change after one week of compression interruption, decreased clearly compared to baseline at the three-year follow-up: 105.7 ±161.0 ml vs. 14.9 ± 174.2 ml. The total lymphedema quality of life (LQOLI) scores improved significantly from baseline to the three-year follow-up (p = 0.02). Within the LQOLI subdomains, physical (p < 0.01) and psychosocial (p = 0.01) scores showed significant improvement over 3 years postoperatively. Six of the 12 participants reduced or discontinued compression garment use within 3 years postoperatively. This group exhibited significantly smaller upper extremity volume differences than those who continued regular compression use (317.8 vs. 923.2 ml, p = 0.04). No serious adverse events were reported, and all the patients remained alive during the four-year follow-up. This prospective multicenter study demonstrated that Lymfactin® with VLNT is safe and well tolerated. Although volume reduction was most evident in the first year, half of the patients reduced or discontinued compression use, and quality of life improved over long-term follow up.

23 August 2024 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Open access
SPSusanna Pajula
Susanna Pajula
ASAnne Saarikko
Anne Saarikko
SSSinikka Suominen
Sinikka Suominen
IKIlkka Kaartinen
Ilkka Kaartinen
JKJuha Kiiski
Juha Kiiski
PHPauliina Hartiala
Pauliina Hartiala
Vascularized lymph node transfer (VLNT) is one option among other surgical treatments in the management of breast cancer-related lymphedema (BCRL). The cause of concern regarding VLNT harvested from the groin has been the potential development of secondary lower-extremity lymphedema. This study explored the risks associated with donor-site morbidity following groin VLNT, with or without concomitant breast reconstruction. The cohort comprised data from the Lymfactin® Phase I and II trials, conducted from 2016 to 2019, that used perioperative reverse lymphatic mapping. The volume of the lower extremities was measured preoperatively and at 3, 6, and 12 months postoperative, and the adverse events were documented during study visits. Altogether, 51 women with a mean age of 55.5 years were recruited. The mean duration of BCRL was 31.8 months. Among these, 25 (49%) underwent VLNT (VLNT-group) and 26 (51%) underwent VLNT in combination with breast reconstruction (VLNT-BR group). The groups were similar in terms of age, (p = 0.766), BMI (p = 0.316), and duration of BCRL (p = 0.994). Across a period of one year, the volume difference between the lower extremities changed by 22.6 ml (range: -813 to 860.2 ml) (p = 0.067). None of the patients had lower-extremity volume difference exceeding 10% at the 12-month follow-up visit. The most frequent adverse events were postoperative pain (17.7%), wound healing issues (11.8%), and seroma formation (11.8%). Most adverse events (64.6%) were classified as minor. This prospective study demonstrated that groin VLNT with reverse lymphatic mapping appears safe and does not increase the risk of secondary donor-site lymphedema within one year postoperatively.

1 January 2021 in Journal of Plastic, Reconstructive & Aesthetic Surgery
Verified
Journal Article
Closed access
SPSusanna Pajula
Susanna Pajula
MGMika Gissler
Mika Gissler
MKMarja Kaijomaa
Marja Kaijomaa
JJJanne Jyränki
Janne Jyränki
ETErkki Tukiainen
Erkki Tukiainen
VKVirve Koljonen
Virve Koljonen